Iatrogenic Kaposi’s sarcoma induced by rituximab and corticosteroid treatment for pemphigus vegetans in an HIV-negative patient

Daflaoui, Hanane; Saddouk, Hasna; Ouadi, Imane; Zizi, Nada; Dikhaye, Siham

doi:10.25259/ijdvl_688_2021

Cited by 4 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Iatrogenic KS often has similar clinical features to the AIDS‐associated KS including fulminant course with widespread lesions, tendency to visceral involvement 19 and poor prognosis. 20 , 21 Tourlaki et al 22 recently reported that 30% of reported cases of pemphigus‐associated KS had visceral involvement and 35% died briefly after diagnosis. A relatively fair course of KS lesions was noted in our case after surgical excision which was one of the most interesting features in this case.…”

Section: Discussionmentioning

confidence: 99%

Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus

et al. 2023

View full text Add to dashboard Cite

Background Kaposi's sarcoma (KS) is a rare multifocal angiogenic tumor often seen in immunocompromised setting such as acquired immunodeficiency syndrome (AIDS) or organ transplantation recipients. Pemphigus vulgaris (PV) is a rare blistering disorder with mucocutaneous involvement for which immunosuppressive therapy has long been the core of treatment. Iatrogenic form of KS has been reported infrequently in pemphigus patients as a result of long‐term immunosuppressive therapy. Case We describe a 39‐year‐old male patient with confirmed diagnosis of PV who developed KS after receiving immunosuppressive agents for his pemphigus. KS was initially localized to the oral cavity with features mimicking exacerbation of his pemphigus. Conclusion This interesting case of KS suggests that dermatologists visiting patients with pemphigus with discomfort in the oral cavity should have a high degree of awareness and consider other differential diagnoses along with merely an exacerbation of PV.

show abstract

Section: Discussionmentioning

confidence: 99%

Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Another report by Daflaoui et al describes the case of an 82-year-old male with pemphigus vegetans that was treated with a total of two doses of rituximab of 1000mg every two weeks [ 38 ]. Three months after the first rituximab dose the patient developed erythematous papules, plaques, and nodules on the right leg, left ankle, hips, and trunk.…”

Section: Reviewmentioning

confidence: 99%

“…Most patients were male and had been treated with multiple immunosuppressive agents alongside rituximab, corticosteroids being the most common. Although most patients were treated with multiple immunosuppressive agents, the case described by Dafloui et al was treated with high-dose rituximab further suggesting the role of rituximab in iKS development [ 38 ]. Opportunistic infections cause systemic inflammation which may promote KS development and progression [ 45 ].…”

Section: Reviewmentioning

confidence: 99%

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review

Oprita,

Cotan,

Celmare

et al. 2023

Cureus

View full text Add to dashboard Cite

Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disorder that requires infection with human herpes virus 8 (HHV-8) for it to develop. It is commonly seen in HIV-positive patients and rarely in immunosuppressed HIV-negative patients. Rituximab is a monoclonal anti-CD20 chimeric murine/human immunoglobulin G antibody used to treat B cell lymphoproliferative diseases as well as a variety of autoimmune disorders. Several cases of iatrogenic Kaposi sarcoma (iKS) have been described after rituximab treatment.The purpose of this narrative review is to identify the presence of common clinical characteristics among rituximab-induced KS patients that could facilitate better management of this rare condition.

show abstract

Prednisone/rituximab

2022

Reactions Weekly

View full text Add to dashboard Cite

Iatrogenic Kaposi’s sarcoma induced by rituximab and corticosteroid treatment for pemphigus vegetans in an HIV-negative patient

Cited by 4 publications

References 13 publications

Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus

Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review

Prednisone/rituximab

Contact Info

Product

Resources

About